Explore Stanford technologies available for licensing:

Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.

Stanford researchers have developed a high-throughput platform to engineer synthetic ETS transcription factors that enhance human T cell function beyond natural TFs, enabling precise and scalable cellular reprogramming for immunotherapy and other therapies.

Stanford researchers have developed a high-throughput platform that designs, delivers, and screens synthetic microRNAs to precisely reprogram human T cells and improve the efficacy of CAR T cell therapies.

Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.

Stanford scientists have developed a generative learning framework paired with a compact wearable EMG device that extrapolates limited sensor inputs to reconstruct muscle activity equivalent to that captured by high-density sensor arrays.

Stanford researchers have created a next-generation platform for producing real meat without raising or slaughtering animals, using a combination of rejuvenated muscle cells and a fully edible, protein-rich scaffold.

Stanford researchers have developed a novel PET agent for diseases stemming from T cell origin. The probes help visualize the disease status as well as the progress of therapy.

Synthetic MRI enables reconstruction of multiple contrasts from a single (multi-echo) scan which significantly improves scanning efficiency.

Stanford researchers have developed an innovative metasurface-enabled, CMOS-compatible platform for high-density, on-chip oligonucleotide synthesis that enables precise, site-selective DNA production without mechanical scanning or complex photolithographic alignment.

Stanford scientists have developed a method and apparatus for simultaneously measuring mucus rheology and cilia activity on live airway cells without removing mucus or inhibiting cilia function.

The blood-brain barrier (BBB) remains a major obstacle to developing effective therapies for neurological and neurodegenerative disease, because most drugs and biologics do not efficiently reach brain tissue.

Scientists at Stanford have developed a new method to manufacture sterile microbial food that contains levels of key bioactive metabolites derived from fermented foods.

Glaucoma results from the loss of retinal ganglion cells (RGCs), the primary output neurons of the retina that connect to brain areas responsible for vision. Current treatments focus on lowering intraocular pressure but do not prevent blindness in about 25% of patients.

Stanford researchers have developed an innovative, integrated diagnostic and therapeutic focused ultrasound (FUS) platform that non-invasively targets peripheral nerves to produce temporary, reversible nerve blockade for acute and chronic pain management.

Stanford scientists have discovered that theta oscillations in the anterior cingulate cortex can detect empathic states, and that targeting the upstream orexin circuit can modulate empathy-related behaviors.